Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02564198 : A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
PhasePhase 1
AgesMin: 12 Months Max: 21 Years
Inclusion Criteria:

- Part A: participants with recurrent or refractory non-CNS solid tumors

- Part B: participants with recurrent or refractory CNS tumors

- Measurable or evaluable disease

- No other therapeutic options

- Performance Status: Karnofsky =50% for participants >16 years and Lansky =50 for
participants =16 years

Exclusion Criteria:

- Active or recent history of serious bleeding events

- Active or recent history of gastrointestinal perforations, ulcers, fistulas or

- Active or recent history of hypertensive crisis or hypertensive encephalopathy

- Active non-healing wound or bone fracture

- History of solid organ transplant
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557